State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 210009, China.
Biomater Sci. 2017 Jul 25;5(8):1367-1381. doi: 10.1039/c7bm00297a.
Combination cancer therapy possesses considerable appeal due to its many merits such as enhancing efficacy by synergistic effects and overcoming drug resistance as compared to monotherapy. Nanomedicine-mediated co-delivery of multiple anticancer agents is more effective than conventional cocktail-based physical mixture of free drugs. A strategy is required to differentiate their unique targets for maximizing the synergistic effects based on individual sites of action of different drugs. This review summarizes the recent progresses in nanomedicine-based combination cancer therapies using site-specific co-delivery strategies, which have been classified by different target sites at the anatomical scales such as tissue, cellular and subcellular levels. In particular, the design of materials and formulations functionalized with tumor-associated signal-responsive elements has been highlighted. The potential and perspective of future developments have also been discussed.
联合癌症疗法具有许多优点，例如通过协同作用增强疗效，与单药治疗相比克服耐药性，因此具有相当大的吸引力。与传统的游离药物基于鸡尾酒的物理混合物相比，纳米医学介导的多种抗癌药物的共递药更有效。需要一种策略来区分它们独特的靶点，以基于不同药物的作用部位最大化协同作用。本综述总结了基于纳米医学的联合癌症疗法的最新进展，这些进展使用了基于不同靶位的特定共递药策略，这些策略根据解剖学尺度（如组织、细胞和亚细胞水平）进行了分类。特别强调了具有肿瘤相关信号响应元件的功能化材料和制剂的设计。还讨论了未来发展的潜力和前景。
